NetScientific PLC PDS Phase 2 Clinical Trial Update (8524P)
21 Outubro 2021 - 10:17AM
UK Regulatory
TIDMNSCI
RNS Number : 8524P
NetScientific PLC
21 October 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Phase 2 Clinical Trial Update
PDS Biotech Provides Update on National Cancer Institute-Led
Phase 2 Clinical Trial of PDS0101-Based Combination
London, UK - 21 October 2021 - NetScientific plc (AIM: NSCI),
the international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB),
has announced the temporary suspension of recruitment in the
National Cancer Institute (NCI)-led Phase 2 clinical trial
(NCT04287868) evaluating PDS0101 (Versamune(R) -HPV16) in
combination with two investigational immune-modulating agents in
advanced HPV cancers.
As indicated by PDS, the issue is not specific to the PDS0101
trial and is unrelated to any safety or efficacy concerns with the
triple combination. It is anticipated that this temporary
suspension in recruitment for this clinical trial will be
determined in a timely manner and is not expected to affect the
overall timing of clinical data. Once resolved, the PDS0101 trial
recruitment will resume immediately.
The trial is evaluating the novel combination in both checkpoint
inhibitor naïve and refractory patients with advanced
HPV-associated cancers that have progressed or returned after
treatment. The vast majority of these cancers are caused by
HPV16.
Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech said:
"We know from the interim data that this combination has the
potential to significantly improve clinical outcomes for patients
with advanced, refractory HPV16-associated cancers who have limited
treatment options. While the trial is experiencing a slight
administrative delay, we are pleased to report that the PDS0101
trial recruitment has progressed well and it is anticipated that it
will resume recruitment shortly. We believe, based on the
previously reported results, that this treatment could
significantly improve survival benefit for these patients, and we
look forward to resumption of the trial in the near term."
Ilian Iliev, CEO of NetScientific, commented: "As indicated by
PDS, it is anticipated that this temporary suspension in
recruitment for this clinical trial will be resolved in a timely
manner and is not expected to affect the overall timing of clinical
data. The issue is not specific to the PDS0101 trial and is
unrelated to any safety or efficacy concerns with the triple
combination. We remain supportive of the PDS strategy and look
forward to clinical data and the next milestones."
Full details of the announcement from PDS can be viewed
here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/569-iotechrovidespdateonationalancernstitutee20211021
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR
Nick Rome/ Paul McManus/ 07748 325 236, 07980 541 893
Nicholas Johnson or 07884 664 686
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: www.netscientific.net ).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESMBBJTMTBTBIB
(END) Dow Jones Newswires
October 21, 2021 09:17 ET (13:17 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024